What is Rincell-1 designed to treat? - Rinri Therapeutics What is Rincell-1 designed to treat? Damage to the auditory neurons of the inner ear can lead to hearing loss Rinri’s first product, Rincell-1, is designed to regenerate these damaged auditory neurons in the inner ears of patients
Our Clinical Research - Rinri Therapeutics Rincell-1 is a cell therapy made of specialised auditory neuron cells grown in the laboratory These cells have the potential to grow into new auditory neurons Laboratory and animal studies have shown that Rincell-1 is safe and able to improve hearing
Rincell-1-A cell therapy for neural hearing loss First-in-human randomised open label trial to assess the safety and feasibility of Rincell-1 otic neuron progenitor cell therapy in addition to standard care, compared with standard care alone in participants with presbycusis, or auditory neuropathy who meet UK guidelines for Cochlear implantation
A New Minimally Invasive Cell Therapy for Hearing Loss Rincell-1 is designed to restore nerve connections between the inner ear and brain, offering a groundbreaking treatment for severe age-related hearing loss and auditory neuropathy The treatment was developed using Rinri’s OSPREY platform, which creates ready-to-use regenerative cell therapies
Cell Therapy for Hearing Loss Enters First Human Trial Called Rincell-1, the treatment aims to regenerate nerve cells in the inner ear that are essential for transmitting sound signals to the brain—cells that no current treatment can replace
First In Human Randomised Trial of Rincell-1 in Adults With a Cochlear . . . Rinri Therapeutics is conducting a clinical trial of a new cell therapy called Rincell-1 Rincell-1 is being developed to treat adults with neural hearing loss, either age related hearing loss or auditory neuropathy, who also meet criteria for a cochlear implant
First Human Trial of Rincell-1 Cell Therapy for Age-Related and Nerve . . . This groundbreaking clinical trial represents the first human study of Rincell-1, an innovative otic neural progenitor cell therapy being tested alongside standard cochlear implantation for patients with specific types of hearing loss